The 2020 updated ASCO /CAP guideline for breast cancer recommended reporting ER positive with 1%–10% of nuclei stained cells as ER low positive category with a recommendation comment, in quote ‘“the cancer in this sample has a low level (1%–10%) of ER expression by IHC’. This evidence concerns the gene ESR1 and breast carcinoma.